Search research articles
Contact Us
Filters
Showing results (591-600 of 711) with videos related to
Page
of 72
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2003
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies
Mitchell A Garrison, Lisa A Hammond, Charles E Geyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors
Casey Cunningham, Leonard J Appleman, Miora Kirvan-Visovatti, et al.
The Journal of Experimental Medicine
|
October 28, 2009
KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C
Thorsten Graef, Achim K Moesta, Paul J Norman, et al.
Blood
|
January 10, 2019
A topological view of human CD34<sup>+</sup> cell state trajectories from integrated single-cell output and proteomic data
David J H F Knapp, Colin A Hammond, Fangwu Wang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 4, 2009
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA
Ralf Lutterbuese, Tobias Raum, Roman Kischel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer
A Patnaik, E K Rowinsky, B K Tammara, et al.
Connecticut Medicine
|
October 27, 2001
A comparison of ON-PUMP vs OFF-PUMP coronary artery bypass surgery among low, intermediate, and high-risk patients: the Hartford Hospital experience
R G McKay, R A Mennett, R C Gallagher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2020
Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma
G Boulle, Y Velut, A Mansuet-Lupo, et al.
Drug and Alcohol Dependence
|
May 22, 2012
Neurobehavioral disinhibition predicts initiation of substance use in children with prenatal cocaine exposure
Barry M Lester, Hai Lin, David S Degarmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2006
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer
Anthony W Tolcher, Desiree Hao, Johann de Bono, et al.
Page
of 72
Search research articles
Search
Showing results (591-600 of 711) with videos related to
Sort By:
Page
of 72
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2003
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies
Mitchell A Garrison, Lisa A Hammond, Charles E Geyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors
Casey Cunningham, Leonard J Appleman, Miora Kirvan-Visovatti, et al.
The Journal of Experimental Medicine
|
October 28, 2009
KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C
Thorsten Graef, Achim K Moesta, Paul J Norman, et al.
Blood
|
January 10, 2019
A topological view of human CD34<sup>+</sup> cell state trajectories from integrated single-cell output and proteomic data
David J H F Knapp, Colin A Hammond, Fangwu Wang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 4, 2009
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA
Ralf Lutterbuese, Tobias Raum, Roman Kischel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer
A Patnaik, E K Rowinsky, B K Tammara, et al.
Connecticut Medicine
|
October 27, 2001
A comparison of ON-PUMP vs OFF-PUMP coronary artery bypass surgery among low, intermediate, and high-risk patients: the Hartford Hospital experience
R G McKay, R A Mennett, R C Gallagher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2020
Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma
G Boulle, Y Velut, A Mansuet-Lupo, et al.
Drug and Alcohol Dependence
|
May 22, 2012
Neurobehavioral disinhibition predicts initiation of substance use in children with prenatal cocaine exposure
Barry M Lester, Hai Lin, David S Degarmo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2006
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer
Anthony W Tolcher, Desiree Hao, Johann de Bono, et al.
Page
of 72